- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01112774
Application of Transcranial Direct Current Stimulation (tDCS) in Patients With Chronic Pain After Spinal Cord Injury
Investigation of the Mechanisms of Transcranial Direct Current Stimulation of Motor Cortex for the Treatment of Chronic Pain in Spinal Cord Injury
The purpose of this study is to determine whether the novel treatment of transcranial direct current stimulation (tDCS) could decrease the pain perception of those with spinal cord injury.
We will also determine whether these changes are correlated with the clinical outcome (pain reduction).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The active tDCS stimulation sessions will be compared to sham stimulation.
More study details will be provided by Spaulding Rehabilitation Hospital.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Spaulding Rehabilitation Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
STUDY ELIGIBILITY CRITERIA (similar to the criteria of the Interstitial Cystitis Network)
- Providing informed consent to participate in the study
- 18 to 64 years old
- with traumatic spinal cord injury (complete or incomplete) - for instance, due to fall, car accident or gun shot; (for spinal cord injury only)
- stable chronic pain for at least the three preceding months(for spinal cord injury only)
- score higher or equal to 4cm (0 cm= 'no pain' and 10cm='worst possible pain') on the Visual Analogue Scale (VAS) for pain perception at the baseline/start of the treatment(for spinal cord injury only)
- refractoriness to drugs for pain relieve - such as tricyclic antidepressants, antiepileptic drugs and/or narcotics (pain resistant to at least 2 of these drugs supplied in adequate dosages for six months) (for spinal cord injury only)
- pain is not attributable to other causes, such as peripheral inflammation.
- No clinically significant or unstable medical or psychiatric disorder
- No history of substance abuse
- No neuropsychiatric comorbidity
- No implanted devices for pain control, such as vagal or deep brain stimulators
No contraindications to tDCS:
- metal in the head
- implanted brain medical devices
- No pregnancy
- Eligible to MRI according to MRI screening checklist.
- No use of ventilators
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: tDCS/Spinal cord injury
Subjects will be randomized to receive 10 sessions of either active or sham tDCS.
Stimulation will be given on consecutive days (Monday- Friday) at 2 mA over the primary motor cortex area.
|
Stimulation will be applied at 2 mA for a total of 20 minutes.
Andre navn:
|
|
Eksperimentell: tDCS/Healthy subjects
Subjects will receive 2 sessions of stimulation: one active and one sham tDCS on two separate visits.
The order in which they receive the stimulation will be randomized.
Stimulation parameters will be at 2 mA for a total of 20 minutes.
|
Stimulation will be applied at 2 mA for a total of 20 minutes.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Neurophysiological activity changes after treatment with tDCS
Tidsramme: baseline, 2 weeks treatment and follow up (2 weeks)
|
Magnetic resonance spectroscopy (MRS), electroencephalogram (EEG), transcranial magnetic stimulation (TMS)
|
baseline, 2 weeks treatment and follow up (2 weeks)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain changes
Tidsramme: Baseline, 2 weeks treatment and follow up (2 weeks)
|
(i) Demographic Data; (ii) Visual analog scale (VAS) for pain; (iii) Analgesic use; (iv) Quality of Life Scale (QOLS); (v) Patient Global Assessment (PGA); (vi) Clinical Global Impression (CGI); (vii) Beck Depression Inventory (BDI); (viii) Visual Analog Scale (VAS) for anxiety; (ix) tDCS Side Effects Questionnaire; (x) Mini-mental status exam; and (xi) Validation of Blinding
|
Baseline, 2 weeks treatment and follow up (2 weeks)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Felipe Fregni, PhD, Spaulding Rehabilitation Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2010p000190
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .